Silver Book Fact

A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.

Ahmed A, Li J, Erlandsson-Harris H, Stark A, et al. Suppression of Pain and Joint Destruction by Inhibition of the Proteasome System in Experimental Osteoarthritis. Pain. 2012; 153(1): 18-26. http://journals.lww.com/pain/Abstract/2012/01000/Suppression_of_pain_and_joint_destruction_by.8.aspx

Reference

Title
Suppression of Pain and Joint Destruction by Inhibition of the Proteasome System in Experimental Osteoarthritis
Publication
Pain
Publication Date
2012
Authors
Ahmed A, Li J, Erlandsson-Harris H, Stark A, et al
Volume & Issue
Volume 153, Issue 1
Pages
18-26
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The Mayo Clinic Pain Rehabilitation Center helps people with persistent pain return to an active lifestyle and has found that among patients who finish the program, nearly 84% report greater…  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • A meta-analysis of duloxetine, an anti-depressant, found a 50% reduction in pain at 12 weeks for diabetic peripheral neuropathy, and a 50% reduction in pain at 12 weeks for fibromyalgia.  
  • A meta-analysis of pscychological interventions for chronic low back pain found small but statistically significant effects for all interventions for as long as 5 years.